NIM
RARE icon

NEOS Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

NEOS Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,599
Closed -$2.53M – 603
2024
Q3 		$2.53M Sell
45,599
-3,319
-7% -$169K 0.08% 232
2024
Q2 		$2.01M Buy
48,918
+17,058
+54% +$728K 0.08% 217
2024
Q1 		$1.49M Buy
31,860
+21,063
+195% +$994K 0.09% 204
2023
Q4 		$516K Buy
+10,797
New +$419K 0.05% 281

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

NEOS Investment Management's RARE Position: Q4 2024 in Review

NEOS Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 45,599 shares — an estimated $2.53M sold.

NEOS Investment Management first reported a position in RARE in Q4 2023 and held it in 4 quarters. The position peaked at $2.53M in Q3 2024. 313 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • NEOS Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • NEOS Investment Management sold 45,599 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $2.53M.
  • NEOS Investment Management first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 4 quarters.
  • NEOS Investment Management's Ultragenyx Pharmaceutical position peaked at $2.53M in Q3 2024.
  • 313 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on NEOS Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.